NARCOLEPSY--MULTICENTER GENETIC AND FAMILY STUDY

据目前所知，嗜睡症是一种中枢神经系统疾病，其特征是睡眠和清醒的失调。嗜睡症并不罕见，大约每1000到2000名北美人中就有1人患有嗜睡症。虽然发作性睡病的遗传尚不清楚，但这种疾病与HLA区域6号染色体亚型[HLA- dr15 （DRB1*1501）和HLA- dq6 (DQBl*0602)]密切相关，但并非总是如此。因此，hla相关和非hla相关形式的存在表明发作性睡病至少是两种疾病。此外，HLA相关型（H+）和非HLA相关型（H -）均以散发的孤立病例（F-）和家族史阳性病例的形式出现。（H+F-），（H+F+）， （H-F-）， （H-F-）， （H-F+）四种类型中的每一种都可能代表不同的病因。这项多中心临床研究资助基于以下几个关键发现：(a)在几个人群中与相同HLA等位基因的强烈关联表明这些等位基因/单倍型可能起作用，(b)只有70%的发作性睡病先证具有HLA相关等位基因，而且他们往往没有受影响的亲属，(c)大多数有多个受影响成员的家庭没有相关的HLA单倍型，(d)一对MZ双胞胎在临床症状方面不同，有/没有中风。(e)先证者一级亲属的睡眠研究揭示了细微的睡眠障碍。我们的总体目标是：(i)通过顺序抽样方案确定额外的113名先知者及其家庭，该方案要求所有被选为先知者的患者符合严格的发作性睡病临床标准（忽略HLA类型），并研究先知者的所有一级亲属。以这种方式进行严格的抽样，避免了因选择“有趣”的家庭而产生的偏倚，并允许准确评估发作性睡病患者与相关HLA型的比例，分离分析发作性睡病和相关临床亚型，以及连锁分析。确定两种家族性发作性睡病的遗传方式。确定相关睡眠障碍症状（如白天过度嗜睡）的家族聚集性和遗传性。（iii）使用先证者系列家族和选定的“高密度”谱系，通过基因组DNA标记筛选和连锁分析绘制非hla相关家族形式的位置。（iv）通过共分离和关联研究来检验hla相关等位基因在发作性睡病中的作用。

Narcolepsy, as presently understood, is a central nervous system disorder characterized by disabling dysregulation of sleep and wakefulness. Narcolepsy is not rare and afflicts about 1 of every 1000 to 2000 North Americans. While the inheritance of narcolepsy is not known, the disorder is strongly, but NOT always, associated with subtypes of the HLA region chromosome 6 [HLA-DR15(DRB1*1501) and HLA-DQ6(DQBl*0602)]. Thus, the presence of HLA-associated and non-HLA associated forms indicates that narcolepsy is at least two disorders. Further, both the HLA associated (H+) and the non-HLA associated ( H - ) form occur as sporadic isolated cases (F-) and family history positive cases. It is possible that each of the four types, (H+F-),(H+F+), (H-F-), (H-F+) represent different etiologies. This Multi-Center Clinical Study grant is based on several key findings: (a) the strong association with the same HLA alleles across several populations indicates a probable role for these alleles/haplotypes, ( b ) only 70 percent of the probands with narcolepsy have the HLA-associated alleles and they tend not to have affected relatives, (c) the majority of families with multiple affected members do not have the associated HLA haplotypes, (d) one pair of MZ twins differs with respect to clinical symptoms, with/without cataplexy, and (e) sleep studies of first degree relatives of probands reveal subtle sleep disturbances. Our overall goals are: (i) Ascertain an additional 113 probands and their families via a sequential sampling scheme which requires that all patients selected as probands meet the strict clinical criteria for narcolepsy (ignoring HLA type) and that all first degree relatives of probands be studied. Rigorous sampling in this manner avoids bias due to selecting "interesting" families and permits accurate evaluation of the proportion of narcoleptics patients with the associated HLA types, segregation analysis for narcolepsy and the related clinical subtypes, as well as linkage analyses. (ii) Identify the modes of inheritance for the two familial forms of narcolepsy. Determine the familial aggregation and inheritance of the related sleep disorder symptoms (e.g., excessive daytime sleepiness). (iii) Using both the proband series families and selected "high density" pedigrees, map the location of the non-HLA associated familial form via a genome DNA marker screen and linkage analyses. (iv) Examine the role of the HLA-associated alleles in narcolepsy through both co-segregation and association studies.